Stockscreener 앱 받기
17.62
1.34%
-0.24
시장 영업 전:
17.70
0.08
+0.45%
Beam Therapeutics Inc 주식(BEAM)의 최신 뉴스
Beam Therapeutics (NASDAQ:BEAM) Price Target Cut to $21.00 by Analysts at Barclays - MarketBeat
BEAM's Q2 Loss Narrower Than Expected, Revenues Miss Mark - MSN
Leerink Partners Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Announces Target Price $42 - 富途牛牛
Beam Therapeutics Receives Buy Rating from Leerink Partners with $42 Price Target - AInvest
Beam Therapeutics: A Narrower Loss in Q2 2025—Sign of a Sustainable Turnaround or a Temporary Bounce? - AInvest
Beam Therapeutics 2025 Q2 Earnings Net Loss Widen Despite EPS Improvement - AInvest
BEAM: Barclays Lowers Price Target with Equal-Weight Rating | BE - GuruFocus
Positive Developments and Financial Strength Bolster Beam Therapeutics’ Buy Rating - TipRanks
Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Misses Revenue Estimates - MSN
Beam Therapeutics Reports Q2 2025 Financial Results - TipRanks
Decoding Beam Therapeutics Inc (BEAM): A Strategic SWOT Insight - GuruFocus
Evaluating the High-Growth Potential of Biopharma Innovators in 2025: A Deep Dive into Day One, Beam Therapeutics, and Syndax Pharmaceuticals - AInvest
Clear Street reiterates Buy rating on Beam Therapeutics stock at $34 - Investing.com
Beam Therapeutics Q2 Net Loss Narrows, Revenue Falls - MarketScreener
Beam Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener
Beam Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Beam (BEAM) Advances in AATD Treatment with Promising BEAM-302 T - GuruFocus
BEAM Reports Q2 Revenue Below Consensus and Highlights Significa - GuruFocus
Beam Therapeutics Q2 net loss widens more than expected - MarketScreener
Beam Therapeutics Inc. SEC 10-Q Report - TradingView
Earnings Flash (BEAM) Beam Therapeutics Posts Q2 $1 Loss, vs. FactSet Est of $1.11 Loss - MarketScreener
Beam Therapeutics Reports Positive Clinical Updates for BEAM-302 and BEAM-101, Financial Results for Q2 2025 - Quiver Quantitative
Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD) - The Manila Times
Beam Therapeutics Reports Second Quarter 2025 Financial - GlobeNewswire
Beam Therapeutics' AATD Treatment Achieves Major Clinical Milestone: 17 Patients Show Durable Disease Correction - Stock Titan
Beam Therapeutics Reports Second Quarter 2025 Financial Results - GuruFocus
When is Beam Therapeutics Inc. stock expected to show significant growthBuild a diversified portfolio for steady growth - Jammu Links News
What makes Beam Therapeutics Inc. stock price move sharplyCapitalize on momentum-driven stocks - Jammu Links News
How many analysts rate Beam Therapeutics Inc. as a “Buy”Unlock real-time stock alerts for quick profits - Jammu Links News
Is it the right time to buy Beam Therapeutics Inc. stockAchieve rapid portfolio growth with expert help - Jammu Links News
Why is Beam Therapeutics Inc. stock attracting strong analyst attentionGrow your wealth with proven stock picks - Jammu Links News
How volatile is Beam Therapeutics Inc. stock compared to the marketMaximize your portfolio’s growth potential - Jammu Links News
What is the risk reward ratio of investing in Beam Therapeutics Inc. stock - Jammu Links News
What are Beam Therapeutics Inc. company’s key revenue driversBoost your returns with professional guidance - Jammu Links News
Is Beam Therapeutics Inc. stock overvalued or undervaluedFree Predictions - Jammu Links News
What are the latest earnings results for Beam Therapeutics Inc.Expert Picks Insights For Fast Growth - jammulinksnews.com
Fmr llc sells Beam therapeutics (BEAM) shares for $991667 By Investing.com - Investing.com Canada
Fmr llc sells Beam therapeutics (BEAM) shares for $991667 - Investing.com
Is Beam Therapeutics Inc. a growth stock or a value stockSwing Trade Opportunities From AI Tools - Jammu Links News
Published on: 2025-08-01 11:56:15 - metal.it
What is Beam Therapeutics Inc. company’s growth strategyMarket Forecast Opportunities For Every Investor - Jammu Links News
Why Beam Therapeutics Inc. stock attracts strong analyst attentionTriple Digit Growth Focused Trade Plan Reviewed - beatles.ru
Beam Therapeutics Inc. stock trendline breakdownReal Time Alerts Based on AI Prediction Triggered - metal.it
Will Beam Therapeutics Inc. Hold Gains Into ClosePotential Breakout Stock List Published This Week - metal.it
Will Beam Therapeutics Inc. (BEAM) Report Negative Q2 Earnings? What You Should Know - Yahoo Finance
Beam Therapeutics Inc. Hits Oversold Level on RSI IndicatorReliable Investment Entry Signals Confirmed by Charts - metal.it
Published on: 2025-07-29 04:04:17 - metal.it
Competitive Positioning of Beam Therapeutics Inc.: Is It Leading or LaggingAlpha Focused Technical Trade Signals Gain Attention - metal.it
0.24%
3.39%
자본화:
|
볼륨(24시간):